InvestmentJul 23, 2026, 04:09 PM
Dyne Therapeutics Closes $431.4M Upsized Public Offering
AI Summary
Dyne Therapeutics, Inc. announced the closing of its upsized underwritten public offering, generating approximately $431.4 million in gross proceeds. The offering included 21,045,000 shares of common stock sold at $20.50 per share, with underwriters fully exercising their option for additional shares. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James acted as joint book-running managers.
Key Highlights
- Gross proceeds from the offering were approximately $431.4 million.
- 21,045,000 shares of common stock were sold in the offering.
- The public offering price was $20.50 per share.
- Underwriters fully exercised their option to purchase an additional 2,745,000 shares.
- All shares in the offering were sold by Dyne Therapeutics.
Price Impact
More from DYN